CVS Health has announced plans to reinstate coverage for Eli Lilly’s weight-loss drug Zepbound starting October 1, and will also add coverage for Lilly’s newly approved oral obesity medication, Foundayo, beginning June 1. The move marks a significant shift in CVS’s formulary strategy, as the company had previously excluded Zepbound from its commercial drug plans. The decision comes amid growing demand for obesity treatments and increased competition in the weight-loss drug market. Zepbound, a tirzepatide injection, and Foundayo, an oral pill, are both designed to help patients manage chronic weight issues. CVS’s inclusion of these drugs is expected to improve patient access to advanced obesity therapies, potentially benefiting Eli Lilly’s market position. The updated coverage will apply to CVS’s commercial and Medicare Part D plans, though specific terms and patient eligibility criteria have not been fully detailed.
Market Outlook
Eli Lilly appears poised for near-term gains as CVS’s coverage expansion could boost prescription volumes for Zepbound and Foundayo. However, pricing pressures and competitive dynamics from Novo Nordisk may temper upside. The stock could see modest positive movement over the next quarter.
Source: CNBC Business
Track how this event may impact global markets at BingX News.
Disclaimer: this content is informational analysis only and does not constitute investment advice.
